Gavreto Receives FDA Approval for RET-Altered Thyroid Cancers

The FDA has approved Genentech’s and Blueprint Medicines’ oral precision therapy Gavreto (pralsetinib) for patients 12 years and older with certain types of rearranged during transfection (RET)-altered thyroid cancer.

The agency’s approval allows the once-daily drug to be used for treating patients 12 and older with advanced or metastatic RET-mutant thyroid cancer who need systemic therapy, or patients with advanced or metastatic RET-fusion-positive thyroid cancer who require systemic therapy and are radioactive iodine refractory, if radioactive iodine is appropriate.

The drug is also approved by the FDA for treating adult patients with RET-fusion-positive nonsmall-cell lung cancer.